Plecanatide, a Novel Uroguanylin Analog: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate Efficacy and Safety in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Dose Ranging ◽

Faculty Opinions recommendation of Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717958672.793516776 ◽

2016 ◽

Author(s):

Robin Spiller

Keyword(s):

Controlled Trial ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

A twelve-week, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging, phase II study to assess the clinical efficacy of alosetron (GR68755) in male subjects with irritable bowel syndrome

The American Journal of Gastroenterology ◽

10.1016/s0002-9270(01)03784-4 ◽

2001 ◽

Vol 96 (9) ◽

pp. S317 ◽

Cited By ~ 1

Author(s):

E EDWARDS1

Keyword(s):

Phase Ii ◽

Clinical Efficacy ◽

Phase Ii Study ◽

Double Blind ◽

Double Blind Placebo ◽

Parallel Group ◽

Dose Ranging ◽

Irritable Bowel ◽

Male Subjects

Efficacy and Safety of Tenapanor in Patients With Constipation Predominant Irritable Bowel Syndrome: A 12-week, Double-Blind, Placebo-Controlled, Randomized Phase 3 Trial

The American Journal of Gastroenterology ◽

10.14309/00000434-201710001-00421 ◽

2017 ◽

Vol 112 ◽

pp. S226-S227 ◽

Cited By ~ 4

Author(s):

William D. Chey ◽

Anthony J. Lembo ◽

Paul Korner ◽

Andrew Yan ◽

David P. Rosenbaum

Keyword(s):

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

459 - Efficacy and Safety of Novel 5-HT4 Agonist DSP-6952 in Patients with Irritable Bowel Syndrome with Constipation: A Randomized, Double-Blind, Placebo-Controlled Early Phase II Study

Gastroenterology ◽

10.1016/s0016-5085(18)30793-5 ◽

2018 ◽

Vol 154 (6) ◽

pp. S-106-S-107 ◽

Cited By ~ 1

Author(s):

Shin Fukudo ◽

Masatoshi Nakamura ◽

Hiroto Miwa

Keyword(s):

Phase Ii ◽

Early Phase ◽

Phase Ii Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Efficacy and Safety of Plecanatide in Patients with Irritable Bowel Syndrome with Constipation: Results from 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trials

Gastroenterology ◽

10.1016/s0016-5085(17)34360-3 ◽

2017 ◽

Vol 152 (5) ◽

pp. S1309-S1310 ◽

Cited By ~ 4

Author(s):

Ronald Fogel ◽

Spencer D. Dorn ◽

Richard Krause ◽

Paul Eng ◽

Robert Kirshoff ◽

...

Keyword(s):

Clinical Trials ◽

Efficacy And Safety ◽

Controlled Clinical Trials ◽

Double Blind ◽

Double Blind Placebo ◽

Faculty Opinions recommendation of Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717958672.793463618 ◽

2012 ◽

Author(s):

David Alpers

Keyword(s):

Controlled Trial ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Efficacy and Safety of Once Daily Linaclotide in Patients With Irritable Bowel Syndrome With Constipation: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial Followed by a 4-Week Randomized Withdrawal Period

Gastroenterology ◽

10.1016/s0016-5085(11)60561-1 ◽

2011 ◽

Vol 140 (5) ◽

pp. S-138 ◽

Cited By ~ 3

Author(s):

Satish Rao ◽

Anthony Lembo ◽

Steven J. Shiff ◽

Kelvin Shi ◽

Jeffrey M. Johnston ◽

...

Keyword(s):

Efficacy And Safety ◽

Withdrawal Period ◽

Phase 3 ◽

Double Blind ◽

Once Daily ◽

Double Blind Placebo ◽

312 Efficacy and Safety of ASP7147, a Bombesin-2 Receptor Antagonist, in Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D): Results of a Multicenter, Double-Blind, Placebo-Controlled Trial

Gastroenterology ◽

10.1016/s0016-5085(15)30241-9 ◽

2015 ◽

Vol 148 (4) ◽

pp. S-69 ◽

Cited By ~ 2

Author(s):

Anthony Lembo ◽

James Huber ◽

Robert M. Schinagl ◽

Stephen J. Waters ◽

M. Scott Harris

Keyword(s):

Receptor Antagonist ◽

Controlled Trial ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Efficacy and Safety of Linaclotide in Patients with Irritable Bowel Syndrome with Constipation: Chinese Sub‐Cohort Analysis of a Phase III , Randomized, Double‐Blind , Placebo‐controlled Trial

Journal of Digestive Diseases ◽

10.1111/1751-2980.13081 ◽

2022 ◽

Author(s):

Lihua Peng ◽

Jingyuan Fang ◽

Ning Dai ◽

Xizhong Shen ◽

Youlin Yang ◽

...

Keyword(s):

Controlled Trial ◽

Cohort Analysis ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Efficacy and safety of drotaverine hydrochloride in irritable bowel syndrome: A randomized double-blind placebo-controlled study

Saudi Journal of Gastroenterology ◽

10.4103/1319-3767.145331 ◽

2014 ◽

Vol 20 (6) ◽

pp. 378 ◽

Cited By ~ 9

Author(s):

RameshR Rai ◽

Manisha Dwivedi ◽

Nirmal Kumar

Keyword(s):

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Drotaverine Hydrochloride ◽